title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Report Forecasts Promising Future for Alzheimer's Disease Market with New Therapeutic Approaches | Brandessence Market Research,20230515T093200,https://www.prnewswire.com/news-releases/report-forecasts-promising-future-for-alzheimers-disease-market-with-new-therapeutic-approaches--brandessence-market-research-301824407.html,AZN,0.03478,Neutral,0.017283
"Geographic Atrophy Market to Boost Significantly, Assesses DelveInsight | Key Companies Active in the Domain - Novartis, Annexon, Apellis, Ionis, Astellas, Gyroscope, Genentech, Aviceda, Iveric Bio",20230628T210100,https://www.prnewswire.com/news-releases/geographic-atrophy-market-to-boost-significantly-assesses-delveinsight--key-companies-active-in-the-domain---novartis-annexon-apellis-ionis-astellas-gyroscope-genentech-aviceda-iveric-bio-301865699.html,AZN,0.077426,Neutral,-0.075581
"The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma | DelveInsight",20231122T220100,https://www.prnewswire.com/news-releases/the-evolving-market-dynamics-of-b-cell-lymphomas-diffuse-large-b-cell-lymphoma-follicular-lymphoma-chronic-lymphocytic-leukemia-mantle-cell-lymphoma-marginal-zone-lymphoma-waldenstrom-macroglobulinemia-and-burkitt-lymphoma--301995626.html,AZN,0.039505,Neutral,0.022299
Emergent BioSolutions Reports Financial Results For Third Quarter 2022,20221108T211600,https://www.globenewswire.com/news-release/2022/11/08/2551487/33240/en/Emergent-BioSolutions-Reports-Financial-Results-For-Third-Quarter-2022.html,AZN,0.049861,Neutral,-0.007995
Emergent BioSolutions  ( EBS )  Q2 2022 Earnings Call Transcript,20220802T033035,https://www.fool.com/earnings/call-transcripts/2022/08/01/emergent-biosolutions-ebs-q2-2022-earnings-call-tr/,AZN,0.006948,Neutral,-0.072951
Emergent BioSolutions Reports Financial Results for Second Quarter 2022,20220801T200500,https://www.globenewswire.com/news-release/2022/08/01/2489875/33240/en/Emergent-BioSolutions-Reports-Financial-Results-for-Second-Quarter-2022.html,AZN,0.021728,Neutral,0.011678
3 Monkeypox Stocks That Soared Last Week,20220523T091300,https://www.fool.com/investing/2022/05/23/3-monkeypox-stocks-that-soared-last-week/,AZN,0.05333,Bearish,-0.554367
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Koninklijke Philips  ( NYSE:PHG ) ,20241028T103251,https://www.benzinga.com/news/24/10/41569352/why-lenz-therapeutics-shares-are-trading-higher-by-around-18-here-are-20-stocks-moving-premarket,AZN,0.071357,Neutral,0.092635
48 Stocks Moving In Friday's Mid-Day Session,20220429T162716,https://www.benzinga.com/news/22/04/26904587/48-stocks-moving-in-fridays-mid-day-session,AZN,0.033034,Neutral,0.002041
70 Biggest Movers From Friday,20220502T094646,https://www.benzinga.com/news/22/05/26923653/70-biggest-movers-from-friday,AZN,0.026319,Neutral,0.005479
"Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight",20240409T214100,https://www.prnewswire.com/news-releases/global-tissue-banking-market-to-exhibit-growth-at-a-considerable-cagr-of-6-by-2030-assesses-delveinsight-302110459.html,AZN,0.045962,Neutral,0.036735
"Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts DelveInsight",20240124T220100,https://www.prnewswire.com/news-releases/drug-eluting-balloons-global-market-is-expected-to-expand-at-a-healthy-growth-rate-of-8-by-2028-predicts-delveinsight-302042856.html,AZN,0.025985,Neutral,0.033663
"Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight",20240115T220500,https://www.prnewswire.com/news-releases/heart-failure-treatment-drug-market-to-accelerate-immensely-by-2032-predicts-delveinsight-302034593.html,AZN,0.046861,Neutral,0.08891
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",20231016T115000,https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-301957344.html,AZN,0.044386,Neutral,0.041683
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",20231016T115000,https://www.newswire.ca/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-816998848.html,AZN,0.044386,Neutral,0.041683
Aquestive  ( AQST )  to Report Q2 Earnings: What's in Store?,20230726T105300,https://www.zacks.com/stock/news/2127563/aquestive-aqst-to-report-q2-earnings-whats-in-store,AZN,0.113329,Neutral,0.0
Colorectal Cancer Treatment Drug Market to Show Immense Growth During the Study Period  ( 2019-2032 )  | DelveInsight,20231121T220100,https://www.prnewswire.com/news-releases/colorectal-cancer-treatment-drug-market-to-show-immense-growth-during-the-study-period-20192032--delveinsight-301994315.html,AZN,0.069227,Neutral,-0.026334
"Hypertension Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - Novartis, Bayer, Merck, Insmed, Acceleron, AbbVie, Alnylam, Apnimed, AstraZeneca, Gossamer Bio",20230719T210100,https://www.prnewswire.com/news-releases/hypertension-market-to-accelerate-positively-estimates-delveinsight--key-companies-active-in-the-market---novartis-bayer-merck-insmed-acceleron-abbvie-alnylam--apnimed-astrazeneca-gossamer-bio-301880558.html,AZN,0.074306,Neutral,0.079746
"Small-Cell Lung Cancer Market to Accelerate Substantially During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Leading Companies - Amgen, Novartis, AbbVie, BMS, Clovis Oncology, Cardiff Oncology, Roche, Daiichi Sankyo",20231004T210100,https://www.prnewswire.com/news-releases/small-cell-lung-cancer-market-to-accelerate-substantially-during-the-study-period-20192032-assesses-delveinsight--leading-companies----amgen-novartis-abbvie-bms-clovis-oncology-cardiff-oncology-roche-daiichi-sankyo-301946615.html,AZN,0.065268,Neutral,-0.046141
"Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate by 2032, Assesses DelveInsight | Key Companies - Merck, Theradex, SynerGene, Mirati, Novartis, Syntrix Biosystems, Eli Lilly, Boehringer Ingelheim",20230803T210100,https://www.prnewswire.com/news-releases/pancreatic-endocrine-tumor-market-is-expected-to-expand-at-a-healthy-growth-rate-by-2032-assesses-delveinsight--key-companies---merck-theradex-synergene-mirati-novartis-syntrix-biosystems-eli-lilly-boehringer-ingelheim-301892397.html,AZN,0.041466,Neutral,-0.038441
"Neuropathy Pain Treatment Market size to grow by USD 5.84 billion from 2023 to 2028, North America accounts for 33 ... - PR Newswire",20231214T221500,https://www.prnewswire.com/news-releases/neuropathy-pain-treatment-market-size-to-grow-by-usd-5-84-billion-from-2023-to-2028--north-america-accounts-for-33-of-market-growth--technavio-302015282.html,AZN,0.078099,Neutral,0.0
"Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer - Bright Minds Biosciences  ( NASDAQ:DRUG ) ",20221123T163529,https://www.benzinga.com/pressreleases/22/11/g29842256/bright-minds-biosciences-appoints-drug-development-executive-mark-a-smith-m-d-ph-d-as-chief-medica,AZN,0.040969,Neutral,-0.067624
"Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer",20221123T163500,https://www.globenewswire.com/news-release/2022/11/23/2561793/0/en/Bright-Minds-Biosciences-Appoints-Drug-Development-Executive-Mark-A-Smith-M-D-Ph-D-as-Chief-Medical-Officer.html,AZN,0.042723,Neutral,-0.067769
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug - Black Diamond Therapeutic  ( NASDAQ:BDTX ) ,20240923T154340,https://www.benzinga.com/general/biotech/24/09/40984991/black-diamond-therapeutics-lead-drug-candidate-shows-initial-anti-tumor-activity-in-certain-type-,AZN,0.209365,Neutral,0.0
"Cell-Free DNA Mutation Diagnostics Market to Surge to US$ 81,584.2 Million by 2034, Growing at a CAGR of 24.9% | Fact.MR Report",20241205T110000,https://www.benzinga.com/pressreleases/24/12/g42334329/cell-free-dna-mutation-diagnostics-market-to-surge-to-us-81-584-2-million-by-2034-growing-at-a-cag,AZN,0.05387,Neutral,0.074754
"Breast Cancer Monoclonal Antibodies Market to grow by USD 15 billion from 2022 to 2027, North America to account ... - PR Newswire",20230918T091500,https://www.prnewswire.com/news-releases/breast-cancer-monoclonal-antibodies-market-to-grow-by-usd-15-billion-from-2022-to-2027-north-america-to-account-for-42-of-market-growth---technavio-301929309.html,AZN,0.043108,Neutral,0.0
"Cutaneous Melanoma Market is Predicted to Exhibit Remarkable Growth, Predicts DelveInsight | Key Companies - Merck, Amgen, Anaveon, Eisai, Regeneron, BMS, AstraZeneca, Seagen, Novartis, Eli Lilly and Company",20230724T210100,https://www.prnewswire.com/news-releases/cutaneous-melanoma-market-is-predicted-to-exhibit-remarkable-growth-predicts-delveinsight--key-companies---merck-amgen-anaveon-eisai-regeneron-bms-astrazeneca-seagen-novartis-eli-lilly-and-company-301883725.html,AZN,0.02692,Neutral,0.029117
Bispecific Antibody Clinical Trial Pipeline Appears Robust With 250+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20230703T210100,https://www.prnewswire.com/news-releases/bispecific-antibody-clinical-trial-pipeline-appears-robust-with-250-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-301868673.html,AZN,0.020404,Neutral,0.115855
Antibody-drug Conjugates Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain,20230626T210100,https://www.prnewswire.com/news-releases/antibody-drug-conjugates-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-180-companies-working-in-the-domain-301862784.html,AZN,0.062651,Neutral,0.067013
Gilead Sciences  ( GILD )  Q4 2022 Earnings Call Transcript,20230203T020023,https://www.fool.com/earnings/call-transcripts/2023/02/02/gilead-sciences-gild-q4-2022-earnings-call-transcr/,AZN,0.004354,Neutral,0.137153
"With 14.1% CAGR, Monoclonal Antibody Therapy Market Size Worth USD 451.89 Billion by 2028",20230130T105418,https://www.benzinga.com/pressreleases/23/01/g30618366/with-14-1-cagr-monoclonal-antibody-therapy-market-size-worth-usd-451-89-billion-by-2028,AZN,0.035983,Neutral,0.073894
"Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know - iShares Biotechnology ETF  ( NASDAQ:IBB ) , BondBloxx ETF Trust BondBloxx BB-Rated USD High Yield Corporate Bond ETF  ( ARCA:XBB ) ",20221101T200154,https://www.benzinga.com/general/biotech/22/11/29508633/provention-bios-second-try-apelliss-eye-disorder-drug-review-3-adcom-verdicts-and-more-novembers-,AZN,0.09402,Neutral,-0.05114
Regenerative Medicine Market is projected to grow at a CAGR of 18.40% by 2033: Visiongain Reports Ltd,20230405T110013,https://www.benzinga.com/pressreleases/23/04/g31675058/regenerative-medicine-market-is-projected-to-grow-at-a-cagr-of-18-40-by-2033-visiongain-reports-lt,AZN,0.028798,Neutral,0.0
Regenerative Medicine Market is projected to grow at a CAGR of 18.40% by 2033: Visiongain Reports Ltd,20230313T110000,https://www.benzinga.com/pressreleases/23/03/g31315741/regenerative-medicine-market-is-projected-to-grow-at-a-cagr-of-18-40-by-2033-visiongain-reports-lt,AZN,0.028798,Neutral,0.0
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer,20220718T133523,https://www.benzinga.com/pressreleases/22/07/g28100211/mimedx-welcomes-kate-surdez-as-chief-human-resources-officer,AZN,0.196877,Neutral,0.121782
MIMEDX Welcomes Kate Surdez as Chief Human Resources Officer,20220718T133500,https://www.globenewswire.com/news-release/2022/07/18/2481141/0/en/MIMEDX-Welcomes-Kate-Surdez-as-Chief-Human-Resources-Officer.html,AZN,0.205225,Neutral,0.128943
"Why Sentage Holdings Shares Are Trading Lower By 5%; Here Are 20 Stocks Moving Premarket - Alarum Technologies  ( NASDAQ:ALAR ) , ARB IOT Group  ( NASDAQ:ARBB ) ",20231226T130058,https://www.benzinga.com/news/23/12/36383191/why-sentage-holdings-shares-are-trading-lower-by-5-here-are-20-stocks-moving-premarket,AZN,0.077094,Somewhat-Bullish,0.196944
"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Catalent, Tesla, DLocal, and Cognyte and Encourages Investors to Contact the Firm - Cognyte Software  ( NASDAQ:CGNT ) , Catalent  ( NYSE:CTLT ) ",20230418T010000,https://www.benzinga.com/pressreleases/23/04/g31845057/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-catal,AZN,0.011195,Neutral,0.030451
"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Catalent, Tesla, DLocal, and Cognyte and Encourages Investors to Contact the Firm - Cognyte Software  ( NASDAQ:CGNT ) , Catalent  ( NYSE:CTLT ) ",20230328T010000,https://www.benzinga.com/pressreleases/23/03/g31522689/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-catal,AZN,0.01119,Neutral,0.03045
"Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Catalent, Tesla, DLocal, and Cognyte and Encourages Investors to Contact the Firm - Cognyte Software  ( NASDAQ:CGNT ) , Catalent  ( NYSE:CTLT ) ",20230318T010000,https://www.benzinga.com/pressreleases/23/03/g31408388/bragar-eagel-squire-p-c-reminds-investors-that-class-action-lawsuits-have-been-filed-against-catal,AZN,0.01119,Neutral,0.03045
"The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis",20241202T100000,https://www.zacks.com/stock/news/2377440/the-zacks-analyst-blog-highlights-roche-poseida-therapeutics-merck-astrazeneca-and-novartis,AZN,0.141448,Neutral,0.032951
"Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success",20241129T200000,https://www.zacks.com/stock/news/2377348/pharma-stock-roundup-rhhby-to-buy-pstx-mrk-azn-see-pipeline-success,AZN,0.144275,Neutral,0.067967
"Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate",20220804T130628,https://www.benzinga.com/general/biotech/22/08/28353376/biotech-daily-amgen-gilead-go-shopping-nod-for-astrazenecas-lynparza-in-early-stage-breast-cancer,AZN,0.09989,Neutral,-0.062416
Nasdaq Turns Higher; Caleres Posts Upbeat Q4 Results - Calix  ( NYSE:CALX ) ,20240319T190235,https://www.benzinga.com/news/earnings/24/03/37830803/nasdaq-turns-higher-caleres-posts-upbeat-q4-results,AZN,0.069094,Somewhat-Bullish,0.197054
"Dow Jumps 200 Points; Core & Main Shares Gain After Q4 Results - Core & Main  ( NYSE:CNM ) , Comtech Telecom  ( NASDAQ:CMTL ) ",20240319T165446,https://www.benzinga.com/news/earnings/24/03/37826515/dow-jumps-200-points-core-main-shares-gain-after-q4-results,AZN,0.067919,Somewhat-Bullish,0.196851
"Nasdaq Down 100 Points; US Housing Starts Surge In February - Enveric Biosciences  ( NASDAQ:ENVB ) , Fusion Pharmaceuticals  ( NASDAQ:FUSN ) ",20240319T134027,https://www.benzinga.com/news/earnings/24/03/37822513/nasdaq-down-100-points-us-housing-starts-surge-in-february,AZN,0.07446,Somewhat-Bullish,0.198246
Why Fusion Pharmaceuticals Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket - Fusion Pharmaceuticals  ( NASDAQ:FUSN ) ,20240319T121056,https://www.benzinga.com/news/24/03/37819142/why-fusion-pharmaceuticals-shares-are-trading-higher-by-around-95-here-are-20-stocks-moving-premarke,AZN,0.068112,Neutral,0.082028
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket,20230119T124819,https://www.benzinga.com/news/23/01/30480367/why-starbox-group-shares-are-trading-higher-by-22-here-are-20-stocks-moving-premarket,AZN,0.077094,Somewhat-Bullish,0.150049
US Stock Market: Top pre-market gainers this morning | The Financial Express,20220809T121156,https://www.financialexpress.com/investing-abroad/featured-stories/us-stock-market-top-pre-market-gainers-this-morning/2623477/,AZN,0.104228,Neutral,0.0
"Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket - Albireo Pharma  ( NASDAQ:ALBO ) , Amryt Pharma  ( NASDAQ:AMYT ) ",20230109T130447,https://www.benzinga.com/news/23/01/30331195/why-cincor-pharma-shares-are-trading-higher-by-140-here-are-20-stocks-moving-premarket,AZN,0.068896,Neutral,0.0
"Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - African Agriculture Hldgs  ( NASDAQ:AAGR ) , Achieve Life Sciences  ( NASDAQ:ACHV ) ",20231212T182222,https://www.benzinga.com/news/23/12/36203637/why-johnson-controls-international-shares-are-trading-lower-by-over-6-here-are-other-stocks-moving-i,AZN,0.049526,Neutral,-0.001993
"Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket - Assembly Biosciences  ( NASDAQ:ASMB ) , Achieve Life Sciences  ( NASDAQ:ACHV ) ",20231212T130008,https://www.benzinga.com/news/23/12/36194643/why-icosavax-shares-are-trading-higher-by-around-45-here-are-20-stocks-moving-premarket,AZN,0.078354,Neutral,0.109398
5 Penny Stocks To Watch After Big News This Week,20230117T142414,https://pennystocks.com/featured/2023/01/17/5-penny-stocks-to-watch-after-big-news-this-week-january-17/,AZN,0.077343,Somewhat-Bullish,0.15316
"The Week Ahead In Biotech  ( June 5-11 ) : Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More",20220605T200922,https://www.benzinga.com/general/biotech/22/06/27558552/the-week-ahead-in-biotech-june-5-11-adcom-test-for-novavax-asco-presentations-enzo-biochem-earnin,AZN,0.121866,Neutral,0.001163
"Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs",20221024T113000,https://www.globenewswire.com/news-release/2022/10/24/2539849/0/en/Reunion-Neuroscience-Appoints-Chief-Financial-Officer-and-Vice-President-Medical-Affairs.html,AZN,0.036812,Neutral,-0.006781
"Reunion Neuroscience Appoints Chief Financial Officer and Vice President, Medical Affairs - Reunion Neuroscience  ( NASDAQ:REUN ) ",20221024T113000,https://www.benzinga.com/pressreleases/22/10/g29376187/reunion-neuroscience-appoints-chief-financial-officer-and-vice-president-medical-affairs,AZN,0.035086,Neutral,-0.006739
"Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte",20230918T210100,https://www.prnewswire.com/news-releases/head-and-neck-squamous-cell-carcinoma-market-to-witness-upsurge-in-growth-by-2032-assesses-delveinsight--key-companies-in-the-market---pfizer-merck-eisai-astrazeneca-innate-roche-glaxosmithkline-beigene-io-biotech-incyt-301930322.html,AZN,0.023146,Neutral,0.04357
Century Therapeutics Announces Leadership Changes,20230412T123000,https://www.globenewswire.com/news-release/2023/04/12/2645337/0/en/Century-Therapeutics-Announces-Leadership-Changes.html,AZN,0.025166,Neutral,-0.003617
Immuno-oncology Consolidating its Presence in Most Major Types of Cancer | Globaldata Plc,20220705T140000,https://www.globenewswire.com/news-release/2022/07/05/2474145/0/en/Immuno-oncology-Consolidating-its-Presence-in-Most-Major-Types-of-Cancer-Globaldata-Plc.html,AZN,0.030755,Neutral,0.003514
S&P 500 Moves Higher; BlackRock Reports Upbeat Results - BlackRock  ( NYSE:BLK ) ,20241011T185856,https://www.benzinga.com/news/earnings/24/10/41297524/s-p-500-moves-higher-blackrock-reports-upbeat-results,AZN,0.071784,Somewhat-Bullish,0.229007
Gold Gains 1%; Wells Fargo Shares Gain After Q3 Earnings - Wells Fargo  ( NYSE:WFC ) ,20241011T164911,https://www.benzinga.com/news/earnings/24/10/41295662/gold-gains-1-wells-fargo-shares-gain-after-q3-earnings,AZN,0.07423,Somewhat-Bullish,0.229708
"Global Precision Medicine Market Size Demonstrates Consistent Growth with a CAGR of 11.12%, with North America Taking a Leading Role - Illumina  ( NASDAQ:ILMN ) , Bristol-Myers Squibb  ( NYSE:BMY ) ",20231108T145000,https://www.benzinga.com/pressreleases/23/11/g35674541/global-precision-medicine-market-size-demonstrates-consistent-growth-with-a-cagr-of-11-12-with-nor,AZN,0.039353,Neutral,0.0
Revvity  ( RVTY )  to Report Q2 Earnings: What's in the Cards?,20230731T124000,https://www.zacks.com/stock/news/2129877/revvity-rvty-to-report-q2-earnings-whats-in-the-cards,AZN,0.049221,Somewhat-Bullish,0.222138
PacBio's  ( PACB )  Latest Offering to Enhance Genome Sequencing,20221024T141000,https://www.zacks.com/stock/news/1996240/pacbios-pacb-latest-offering-to-enhance-genome-sequencing,AZN,0.085782,Neutral,0.066685
"Daily Biotech Pulse: KKR Invests In Medicine Start-Up, Revelation Bio Aces Allergic Rhinitis Study, Tonix Pharma Ends COVID-19 Antiviral Pact",20220725T132056,https://www.benzinga.com/general/biotech/22/07/28185526/daily-biotech-pulse-kkr-invests-in-medicine-start-up-revelation-bio-aces-allergic-rhinitis-study-,AZN,0.216376,Neutral,0.11053
U.S. Stock Futures Higher; Crude Oil Rises 1%,20220725T103541,https://www.benzinga.com/news/earnings/22/07/28183418/u-s-stock-futures-higher-crude-oil-rises-1,AZN,0.152018,Neutral,0.143364
AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC,20241223T155600,https://www.zacks.com/stock/news/2386987/azns-tagrisso-gets-approval-in-the-eu-for-expanded-use-in-nsclc,AZN,0.389744,Neutral,0.057648
AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study,20241126T191800,https://www.zacks.com/stock/news/2375636/astrazenecas-combination-therapy-meets-goal-in-prostate-cancer-study,AZN,0.544246,Somewhat-Bearish,-0.29585
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC,20241119T132300,https://www.zacks.com/stock/news/2371987/chmp-endorses-astrazenecas-tagrisso-for-expanded-use-in-nsclc,AZN,0.387875,Neutral,-0.038241
AstraZeneca's  ( AZN )  sBLA for Enhertu Gets FDA's Priority Tag,20240130T124400,https://www.zacks.com/stock/news/2217677/astrazenecas-azn-sbla-for-enhertu-gets-fdas-priority-tag,AZN,0.412017,Neutral,0.12185
AstraZeneca's  ( AZN )  Imfinzi Combo Meets Liver Cancer Study Goal,20240122T194200,https://www.zacks.com/stock/news/2213719/astrazenecas-azn-imfinzi-combo-meets-liver-cancer-study-goal,AZN,0.488217,Neutral,0.130886
Merck's  ( MRK )  Keytruda-Lynparza Combo Fails Lung Cancer Study,20231208T164400,https://www.zacks.com/stock/news/2195640/mercks-mrk-keytruda-lynparza-combo-fails-lung-cancer-study,AZN,0.24289,Neutral,-0.094988
AstraZeneca  ( AZN )  to Discontinue Two Studies on Lokelma,20231201T162700,https://www.zacks.com/stock/news/2192314/astrazeneca-azn-to-discontinue-two-studies-on-lokelma,AZN,0.305058,Neutral,0.018063
AbbVie  ( ABBV )  Posts Encouraging Data From Lung Cancer Study,20231130T165600,https://www.zacks.com/stock/news/2191706/abbvie-abbv-posts-encouraging-data-from-lung-cancer-study,AZN,0.11983,Neutral,0.132592
"Triple-Negative Breast Cancer Market to Accelerate Substantially During the Forecast Period  ( 2023-2032 ) , Examines DelveInsight | Key Companies to Watch - Roche, AbbVie, AstraZeneca, BeiGene, GlaxoSmithKline, Genentech, Eli Lilly, Novartis",20230906T210100,https://www.prnewswire.com/news-releases/triple-negative-breast-cancer-market-to-accelerate-substantially-during-the-forecast-period-20232032-examines-delveinsight--key-companies-to-watch---roche-abbvie-astrazeneca-beigene-glaxosmithkline-genentech-eli-lilly--301918858.html,AZN,0.04497,Neutral,0.005975
"Gout Market to Accelerate Positively, Estimates DelveInsight | Key Companies Active in the Market - InventisBio, Allena, Olatec, Shanton, LG Chem, Arthrosi, Jiangsu Hengrui Medicine, AstraZeneca, R-Pharm, Arrowhead, Horizon",20230704T210100,https://www.prnewswire.com/news-releases/gout-market-to-accelerate-positively-estimates-delveinsight--key-companies-active-in-the-market---inventisbio-allena-olatec-shanton-lg-chem-arthrosi-jiangsu-hengrui-medicine-astrazeneca-r-pharm-arrowhead-horizon-301869396.html,AZN,0.029327,Neutral,0.105816
3 Stocks Under $1 Insiders Are Buying,20220614T122254,https://www.benzinga.com/trading-ideas/long-ideas/22/06/27694155/3-stocks-under-1-insiders-are-buying,AZN,0.103778,Neutral,0.010794
"Large Granular Lymphocyte Leukemia Market is Projected to Grow During the Study Period  ( 2019-2032 ) , Assesses DelveInsight | Key Companies - Bristol Myers Squibb, Innate Pharma, Kymera Therapeutics, EUSA Pharma, Abcuro, Dren Bio, Novotech",20231016T210100,https://www.prnewswire.com/news-releases/large-granular-lymphocyte-leukemia-market-is-projected-to-grow-during-the-study-period-20192032-assesses-delveinsight--key-companies---bristol-myers-squibb-innate-pharma-kymera-therapeutics-eusa-pharma-abcuro-dren-bio-n-301957023.html,AZN,0.077426,Neutral,-0.029504
"Acute Lymphocytic Leukemia Market to Accelerate Substantially by 2032, Assesses DelveInsight | Key Companies in the Market - Beam, Pfizer, Genentech, AbbVie, Fate, Roche, Ascentage, Janssen, Jazz, ADC, Kymera, Syndax, ImmunoGen",20230913T210100,https://www.prnewswire.com/news-releases/acute-lymphocytic-leukemia-market-to-accelerate-substantially-by-2032-assesses-delveinsight--key-companies-in-the-market---beam-pfizer-genentech-abbvie-fate-roche-ascentage-janssen-jazz-adc-kymera-syndax-immunogen-301925772.html,AZN,0.021897,Neutral,0.0
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer,20230206T120000,https://www.globenewswire.com/news-release/2023/02/06/2601922/0/en/LAVA-Therapeutics-Announces-the-Appointment-of-Dr-Charles-Morris-as-Chief-Medical-Officer.html,AZN,0.044304,Neutral,-0.015964
LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20230206T120000,https://www.benzinga.com/pressreleases/23/02/g30725682/lava-therapeutics-announces-the-appointment-of-dr-charles-morris-as-chief-medical-officer,AZN,0.043342,Neutral,-0.014945
LAVA Therapeutics Announces Appointment of New Directors to the Board - LAVA Therapeutics  ( NASDAQ:LVTX ) ,20230106T180754,https://www.benzinga.com/pressreleases/23/01/g30314713/lava-therapeutics-announces-appointment-of-new-directors-to-the-board,AZN,0.053629,Neutral,-0.002992
LAVA Therapeutics Announces Appointment of New Directors to the Board,20230106T180700,https://www.globenewswire.com/news-release/2023/01/06/2584625/0/en/LAVA-Therapeutics-Announces-Appointment-of-New-Directors-to-the-Board.html,AZN,0.055109,Neutral,-0.002996
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight,20240711T213100,https://www.prnewswire.com/news-releases/molecular-glues-clinical-trial-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment--delveinsight-302194515.html,AZN,0.074615,Neutral,-0.053652
"Immix Biopharma Announces Dr. Suzanne Lentzsch, Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York, Joins Scientific Advisory Board",20230901T123900,https://www.globenewswire.com/news-release/2023/09/01/2736017/0/en/Immix-Biopharma-Announces-Dr-Suzanne-Lentzsch-Director-of-the-Multiple-Myeloma-and-Amyloidosis-Program-at-the-College-of-Physicians-and-Surgeons-of-Columbia-University-and-at-New-Y.html,AZN,0.087397,Neutral,0.002073
